Area of research
Physiology · Biomaterials
Research interest
Research interests include Pain Mechanisms and Treatments, Nanoparticle-Based Drug Delivery, Advanced Drug Delivery Systems, and Molecular Sensors and Ion Detection.
Tetrodotoxin Delivery Pen Safely Uses Potent Natural Neurotoxin to Manage Severe Cutaneous Pain
Nitro Indole Derivatives as Novel Dual-Polarity Matrices for MALDI Mass Spectrometry and Imaging with Broad Applications
Galacturonic acid-capsaicin prodrug for prolonged nociceptive-selective nerve blockade
Exosomal Bupivacaine: Integrating Nerve Barrier Penetration Capability and Sustained Drug Release for Enhanced Potency in Peripheral Nerve Block and Reduced Toxicity
Quantitative MALDI-MS and Imaging of Fungicide Pyrimethanil in Strawberries with 2-Nitrophloroglucinol as an Effective Matrix
Capsaicin-Loaded Melanin Nanoparticles for Long-Lasting Nociceptive-Selective Nerve Blockade
Drug Permeability: From the Blood–Brain Barrier to the Peripheral Nerve Barriers
Hydration‐Induced Void‐Containing Hydrogels for Encapsulation and Sustained Release of Small Hydrophilic Molecules
Mortality Risk Factors and Prognostic Analysis of Patients with Multi-Drug Resistant Enterobacterales Infection
Emulsion‐Induced Polymersomes Taming Tetrodotoxin for Prolonged Duration Local Anesthesia
Zero-Order Controlled Release of Water-Soluble Drugs Using a Marker Pen Platform
Co-Production of NDM-1, CTX-M-9 Family and mcr-1 in a Klebsiella pneumoniae ST4564 Strain in China
Strategies to Obtain Encapsulation and Controlled Release of Small Hydrophilic Molecules
<p>Emergence of NDM-5-Producing Carbapenem-Resistant <em>Klebsiella pneumoniae</em> and SIM-Producing Hypervirulent <em>Klebsiella pneumoniae</em> Isolated from Aseptic Body Fluid in a Large Tertiary Hospital, 2017–2018: Genetic Traits of <em>bla</em>NDM-Like and <em>bla</em>SIM-Like Genes as Determined by NGS</p>
Percutaneous delivery of econazole using microemulsion as vehicle: Formulation, evaluation and vesicle-skin interaction
Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment